

1 **Simultaneous Detection and Mutation Surveillance of SARS-CoV-2 and co-infections of multiple**  
2 **respiratory viruses by Rapid field-deployable sequencing**

3  
4 **Authors:** Chongwei Bi<sup>1</sup>, Gerardo Ramos-Mandujano<sup>1</sup>, Sharif Hala<sup>1, 2, 3</sup>, Jinna Xu<sup>1</sup>, Sara Mfarrej<sup>1</sup>, Yeteng  
5 Tian<sup>1</sup>, Concepcion Rodriguez Esteban<sup>4</sup>, Estrella Nuñez Delicado<sup>5</sup> Fadwa S. Alofi<sup>6</sup>, Asim Khogeer<sup>7</sup>, Anwar  
6 M. Hashem<sup>8, 9</sup>, Naif A.M. Almontashiri<sup>10, 11</sup>, Arnab Pain<sup>1</sup>, Juan Carlos Izpisua Belmonte<sup>4, \*</sup>, Mo Li<sup>1, \*</sup>

7  
8 **Affiliations:**

9 1 Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of  
10 Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia

11 2 King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia

12 3 King Abdullah International Medical Research Centre, Jeddah, Makkah, Ministry of National Guard  
13 Health Affairs, Jeddah, Makkah, Saudi Arabia

14 4 Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La  
15 Jolla, CA, 92037, USA

16 5 Universidad Católica San Antonio de Murcia (UCAM), Campus de los Jerónimos, Nº 135 12 Guadalupe  
17 30107, Spain.

18 6 Infectious Diseases Department, King Fahad Hospital, Madinah, Saudi Arabia

19 7 Plan and Research Department, General Directorate of Health Affairs Makkah Region, MOH, Saudi  
20 Arabia

21 8 Vaccines and Immunotherapy Unit, King Fahd Medical Research Center; King Abdulaziz University,  
22 Jeddah, Saudi Arabia

23 9 Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University,  
24 Jeddah, Saudi Arabia

25 10 College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia

26 11 Center for Genetics and Inherited Diseases, Taibah University, Madinah, Saudi Arabia

27 \* Correspondence: [Belmonte@salk.edu](mailto:Belmonte@salk.edu) (JCIB) and [mo.li@kaust.edu.sa](mailto:mo.li@kaust.edu.sa) (ML)

28

## 1 **Abstract**

2

3 Strategies for monitoring the COVID-19 infection are crucial for combating the pandemic. Here we  
4 describe a method for multiplex isothermal amplification-based sequencing and real-time analysis of  
5 multiple viral genomes. It can simultaneously detect SARS-CoV-2 and co-infecting respiratory viruses,  
6 and monitor mutations for up to 96 samples in real time. The method, termed NIRVANA for Nanopore  
7 sequencing of Isothermal Rapid Viral Amplification for Near real-time Aalysis, showed high sensitivity  
8 and specificity for SARS-CoV-2 in 70 clinical samples. It also simultaneously detected other viral  
9 pathogens (e.g. influenza A) in clinical and municipal wastewater samples. It provides a rapid field-  
10 deployable solution of COVID-19 and co-infection detection and surveillance of the evolution of  
11 pandemic strains.

12

## 13 **Main**

### 14 **Introduction**

15 The novel coronavirus disease (COVID-19) pandemic is one of the most serious challenges to public  
16 health and global economy in modern history. SARS-CoV-2 is a positive-sense RNA betacoronavirus that  
17 causes COVID-19<sup>1</sup>. It was identified as the pathogenic cause of an outbreak of viral pneumonia of  
18 unknown etiology in Wuhan, China, by the Chinese Center for Disease Control and Prevention (CCDC) on  
19 Jan 7, 2020<sup>2</sup>. Three days later, the first SARS-CoV-2 genome was released online through a collaborative  
20 effort by scientists in universities in China and Australia and Chinese public health agencies (GenBank:  
21 MN908947.3)<sup>3</sup>. One week after the publication of the genome the first diagnostic detection of SARS-  
22 CoV-2 using real-time reverse transcription polymerase chain reaction (rRT-PCR) was released by a  
23 group in Germany<sup>4</sup>.

24

25 To date, rRT-PCR assays of various designs, including one approved by the US Centers for Disease  
26 Control and Prevention (US CDC) under emergency use authorization (EUA)<sup>5</sup>, have remained the  
27 predominant diagnostic method for SARS-CoV-2. Although proven sensitive and specific for providing a  
28 positive or negative answer, rRT-PCR provides little information on the genomic sequence of the virus,  
29 knowledge of which is crucial for monitoring how SARS-CoV-2 is evolving and spreading and ensuring  
30 successful development of new diagnostic tests and vaccines. To this end, samples need to go through a  
31 separate workflow—typically Illumina shotgun metagenomics or targeted next-generation sequencing  
32 (NGS)<sup>6</sup>. Because NGS requires complicated molecular biology procedures and high-value instruments in  
33 centralized laboratories, it is performed in < 1% as many cases as rRT-PCR, evidenced by the number of

1 genomes in the GISAID database (39,954) and confirmed global cases tallied by the WHO (6,535,354) as  
2 of June 5, 2020.

3  
4 SARS-CoV-2 infections often cause symptoms similar to other respiratory viruses, thus making it  
5 challenging to distinguish co-infection especially in the flu season. Several studies have reported co-  
6 infection of SARS-CoV-2 and other respiratory viruses—respiratory syncytial virus (RSV) and influenza  
7 being the most common viral pathogens identified<sup>7,8</sup>, and influenza was particularly high in dead  
8 patients<sup>9</sup>. The detection of co-infection is potentially useful for monitoring the SARS-CoV-2 pandemic  
9 and benefiting the treatment of patients. To date, no method can rapidly diagnose multiple viral  
10 infections in a high-throughput manner. Ideally, such methods should be field-deployable to allow  
11 timely assessment of outbreaks anywhere anytime.

12  
13 Both rRT-PCR and NGS are sophisticated techniques whose implementation is contingent on the  
14 availability of highly-specialized facilities, personnel and reagents. These limitations could translate into  
15 long turn-over time and inadequate access to tests even in developed countries. To address these issues,  
16 several PCR-free nucleic acid detection assays have been proposed as point-of-care replacements of rRT-  
17 PCR. Chief among them is reverse transcription coupled loop-mediated isothermal amplification (RT-  
18 LAMP<sup>10</sup>), which has been used for rapid detection of SARS-CoV-2 RNA<sup>11-14</sup>. On the sequencing front, the  
19 pocket-sized Oxford Nanopore MinION sequencer has been used for rapid pathogen identification in the  
20 field<sup>15,16</sup>. Because MinION offers base calling on the fly, it is an attractive platform for consolidating viral  
21 nucleic acid detection by PCR-free rapid isothermal amplification and viral mutation monitoring by  
22 sequencing. However, there are several challenges for an integrated point-of-care solution based on RT-  
23 LAMP and Nanopore sequencing. RT-LAMP requires a complex mixture of primers that increases the  
24 chance of non-specific amplification and makes it difficult to multiplex. Additionally, LAMP amplicons  
25 used for SARS-CoV-2 detection are short<sup>12,13</sup>. Sequencing singleplex short amplicons not only fails to take  
26 advantage of the long-read and sequencing throughput (~10 Gb) of the MinION flow cell, it is also prone  
27 to false negative reporting due to amplification failure. To the best of our knowledge, no multiplexed  
28 isothermal amplification of SARS-CoV-2 has been reported. Nanopore sequencing has its own caveats  
29 too. Due to its relatively high basecalling error, new bioinformatics tools based on dedicated  
30 algorithms<sup>17,18</sup> are also needed to accurately call the presence of viral sequences (substituting for rRT-PCR)  
31 and analyze virus mutations (substituting for NGS).

32

1 Here we developed isothermal recombinase polymerase amplification (RPA) assays to simultaneously  
2 amplify multiple regions (up to 2184 bp) of the SARS-CoV-2 genome and three respiratory viruses. This  
3 forms the basis for an integrated workflow to detect the presence of viral sequences and monitor  
4 mutations in multiple regions of the SARS-CoV-2 genome in up to 96 patients at a time (Fig. 1a). We  
5 developed a bioinformatics pipeline for on-the-fly analysis to reduce the time to answer and sequencing  
6 cost by stopping the sequencing run when data are sufficient to provide confident answers.

7

## 8 **Results**

9 Singleplex RPA was first performed to test its ability to amplify the SARS-CoV-2 genome from a  
10 nasopharyngeal swab sample tested positive for the virus using the US CDC assays<sup>5</sup> (CT value=21).  
11 Sixteen primers were tested in 12 combinations to amplify 5 regions harboring either reported signature  
12 mutations<sup>19,20</sup> useful for strain classification or mutation hotspots (GISAID, as of March 15, 2020). Five  
13 pairs of primers showed robust amplification of DNA of predicted size (range: 194-466 bp) in a 20-min  
14 isothermal reaction at 39 °C (Fig. 1b, Supplementary Fig. 1a). The specificity of all 5 RPA products was  
15 verified by restriction enzyme digestion (Supplementary Fig. 1b). The limit of detection of RPA reaches  
16 below 10 copies (Supplementary Fig. 1c). Furthermore, we showed that these RPA reactions could be  
17 multiplexed to amplify the five regions of the SARS-CoV-2 genome in a single reaction (Fig. 1c), thus  
18 significantly simplifying the workflow.

19

20 We next performed multiplex RPA using ten SARS-CoV-2 positive samples (SARS-CoV-2<sup>+</sup>, determined by  
21 US CDC assays<sup>5</sup>, CT value range: 15 to 27.9). Multiplex RPA products of the 10 samples were individually  
22 barcoded, pooled and prepared into a Nanopore sequencing library using an optimized protocol to save  
23 time. The whole workflow from RNA to sequencing took approximately 4 hours (Fig. 1a). The barcoded  
24 library was sequenced on a Nanopore MinION using a R9.4.1 flow cell. After 12-h sequencing, we  
25 acquired a total of 1.7 million reads from this barcoded library (Supplementary Fig. 2a). The  
26 demultiplexed reads were distributed relatively evenly among the barcodes (samples). We further  
27 aligned the reads to the SARS-CoV-2 reference genome and found that all RPA amplicons were covered  
28 by thousands of reads in all samples, suggesting that barcoded multiplexed RPA sequencing worked  
29 effectively (Fig. 1d, Supplementary Fig. 2b).

30

31 The identification of a SARS-CoV-2 positive sample can be achieved by surveying the existence of  
32 targeted amplicons via sequencing. However, the determination of negative samples needs to rule out

1 potential sample collection failure, thus requiring a sample quality validation control. We used the  
2 existence of transcripts of the human housekeeping gene *ACTB* as a quality check of sample collection.  
3 The sequencing results showed that the *ACTB* gene could be effectively amplified without significantly  
4 affecting the amplification of SARS-CoV-2 ([Supplementary Fig. 2c](#)).

5  
6 Co-infection with other respiratory pathogens in COVID-19 patients has been evaluated, however,  
7 current detection of co-infections requires additional rRT-PCR assays<sup>9,21,22</sup> or NGS<sup>8</sup>. Such ad hoc tests are  
8 not amenable to large-scale screening of co-infections. On the other hand, multiplexed RPA of different  
9 viruses could be a promising solution to detect co-infections in a timely and efficient manner.

10  
11 As a proof-of-principle of multiplex RPA of multiple human viral pathogens, we screened and validated  
12 RPA primers that robustly amplify influenza A (FluA), human adenovirus (HAdV), and non-SARS-CoV-2  
13 human coronavirus (HCoV), respectively (data not shown). We added the three pairs of respiratory virus  
14 primers to the multiplex SARS-CoV-2 RPA panel to achieve simultaneous isothermal amplification of four  
15 viral pathogens ([Supplementary table 1](#)). To ensure effective amplification of all targets, we adjusted the  
16 concentration of each primer pair based on the read depth of the cognate genomic region when  
17 sequencing a contrived co-infection sample made from a SARS-CoV-2<sup>+</sup> sample spiked with a control  
18 panel of 21 respiratory viruses including FluA, HAdV, and HCoV (Respiratory21<sup>+</sup>). The final primer mix  
19 achieved amplification of all targeted amplicons ([Fig. 2a](#)).

20  
21 The presence of SARS-CoV-2 has been reported in municipal sewage, of which the viral load was found  
22 to be correlated to the reported COVID-19 prevalence<sup>23</sup>. This suggests that wastewater surveillance  
23 could be a sensitive indicator of total COVID-19 case load (including asymptomatic cases) in the  
24 population. To evaluate the possibility of using multiplex RPA to detect SARS-CoV-2 in wastewater, we  
25 determined the primer mix to simultaneously amplify five regions of SARS-CoV-2 and one region of  
26 pepper mild mottle virus (PMMoV, an omnipresent indicator of water quality<sup>24</sup>). We spiked the  
27 wastewater concentrate (see methods) with RNA of SARS-CoV-2 positive samples, and used this as a  
28 positive control to test the multiplex RPA. Two primer mixes with different concentration of PMMoV  
29 primers were tested. Both primer mixtures can detect the SARS-CoV-2 and PMMoV within the positive  
30 control ([Supplementary Fig. 2d](#)). These results suggest that multiplex RPA can be used to monitor the  
31 presence of SARS-CoV-2 and other viruses in municipal wastewater. In addition, because the

1 simultaneous acquisition of viral sequences, this method can also survey the strains circulating in the  
2 population (see below).

3  
4 We next performed multi-virus multiplex RPA assay followed by Nanopore sequencing in 60 clinical  
5 samples suspected of SARS-CoV-2 infection. Following RT and RPA (Fig. 1a), amplicons of each sample  
6 were barcoded and sequenced in one Nanopore MinION flow cell. To take advantage of the unique  
7 feature of real-time base-calling offered by Nanopore sequencing, we developed a bioinformatics  
8 algorithm termed Real-Time Nanopore sequencing monitor (RTNano) (Fig. 1e). RTNano continuously  
9 monitors the output folder of basecalled data during the sequencing run and generates analysis reports  
10 in a matter of seconds. After detecting new fastq files (basecalled sequence output format of Nanopore  
11 sequencing), RTNano quickly aligns the reads to the targeted amplicons of the viruses. To confidently  
12 determined the existence of a virus, RTNano filters the alignment records by percentage identity and  
13 amplicon coverage and provides the number of positive records for each targeted viral amplicon, which  
14 is then used to evaluate the infection status of the sample.

15  
16 When demultiplexing a large number of samples, barcode misclassification could potentially happen due  
17 to base-calling errors in the barcodes. RTNano includes an additional round of demultiplexing using  
18 stringent parameters to reduce the chance of barcode misclassification (see methods). Furthermore, a  
19 no template control (NTC) is included to monitor barcode misclassification. The reads of targeted  
20 amplicons assigned to the NTC barcode likely represented background errors in demultiplexing. The  
21 positive record number of the NTC will be subtracted from individual sample analysis to further reduce  
22 false positive identification. After the real-time analysis, RTNano generates a report for each of the 60  
23 sample, including current read number, base number, and details of alignment positive records (Fig. 1e).  
24 To simplify the interpretation of the result, RTNano provides a summary score of SARS-CoV-2 based on  
25 predefined rules (Supplementary table 2). SARS-CoV-2 positive samples (POS) are assigned with  
26 different confidence levels based on the number of covered amplicons and corresponding positive  
27 records, range from 0 to 3 (lowest to highest). When there is no record of SARS-CoV-2, the sample could  
28 be categorized as either negative (NEG) if there are enough records of *ACTB*; or unknown (UKN) if there  
29 are insufficient records of *ACTB*. The introduction of confidence level can improve the accuracy of  
30 diagnosis, which is in principle similar to the CT value of rRT-PCR but based on quantitative information  
31 of multiple amplicons. Since base calling and demultiplexing may lead to a brief delay, we refer to the

1 workflow as Nanopore sequencing of Isothermal Rapid Viral Amplification for Near real-time Aalysis  
2 (NIRVANA) (Fig. 1a).

3  
4 RTNano identified 35 SARS-CoV-2 positive cases in the 60 samples after 2 hours of Nanopore sequencing.  
5 Ten more positives were identified by RTNano (RTNano<sup>+</sup>) as data output increased in the next 22 hours  
6 of sequencing (Fig. 2b, Supplementary File 1). An identical aliquot of each sample was analyzed in  
7 parallel using the US CDC rRT-PCR SARS-CoV-2 assays, 57 samples were confirmed as SARS-CoV-2  
8 positive or negative, while 3 samples were inconclusive after two rounds of tests (Supplementary File 2).  
9 We excluded the 3 inconclusive samples in the downstream analysis. Among the analyzed 43 RTNano<sup>+</sup>  
10 samples, 41 (95.35%) were also considered positive by the rRT-PCR assay (PCR<sup>+</sup>). The two remaining  
11 weakly RTNano<sup>+</sup> sample (POS\_0) had high CT values of RNase P and failed in PCR amplification of N1 and  
12 N2. Three of the RTNano<sup>-</sup> samples were also PCR<sup>-</sup> due to failed amplification of N1 and/or N2, while the  
13 rest of 11 RTNano<sup>-</sup> were PCR<sup>+</sup>. These 11 false-negative samples had high CT values (N1:  $34.16 \pm 0.36$ , N2:  
14  $36.27 \pm 0.47$ , Fig. 2c). The incorrect identification of these samples could be due to amplification failure  
15 of multiplex RPA or insufficient sequencing throughput. In addition, high CT values in SARS-CoV-2 rRT-  
16 PCR test have a higher chance of being false-positive<sup>25,26</sup>.

17  
18 We calculated the average CT value of RTNano<sup>+</sup> samples under different confidence levels. RTNano<sup>+</sup>  
19 samples with high confidence level correlated with lower CT values, which proved the reliability of  
20 RTNano results (Fig. 2d). Based on the N1 standard curve, we estimated the limit of detection (LoD) of  
21 NIRVANA was ~29 viral RNA copies/ $\mu$ l of extracted nucleic acid (86 copies per reaction, based on  
22 average N1 CT value of 33.37 of POS\_0, and see methods), which was comparable to the current rRT-  
23 PCR assays<sup>27</sup>.

24  
25 We next surveyed co-infection of three common respiratory viruses in the 60 samples. The ground truth  
26 of the FluA co-infection was determined by both in vitro diagnostic kit (CE-IVD) Resp'Easy<sup>TM</sup> and IDT  
27 Influenza/RSV primers. Four samples were identified as FluA<sup>+</sup> in both assays with CT values from 33.97  
28 to 39.33 (by Resp'Easy<sup>TM</sup>) (Supplementary Fig. 2e). RTNano detected the FluA<sup>+</sup> sample with the lowest CT  
29 value (sample 46, CT 33.97) with high confidence (Fig. 2e). The HAdVs and HCoV co-infection was  
30 examined using the Resp'Easy<sup>TM</sup> kit, and only one HCoV<sup>+</sup> sample was identified (Resp'Easy<sup>TM</sup> CT=35.18).  
31 RTNano reported no HAdVs co-infection, while failed to detect the HCoV<sup>+</sup> sample.

32

1 A high level of multiplexing reactions could negatively affect RPA efficiency of each amplicon. To test if a  
2 less complex primer combination could improve the performance of NIRVANA, we removed less robust  
3 SARS-CoV-2 primers (pair 9 & 10) and performed a new NIRVANA sequencing. Twenty-nine of the 60  
4 samples were sequenced, including 11 RTNano<sup>-</sup>/PCR<sup>+</sup>, 4 FluA<sup>+</sup>, and 1 HCoV<sup>+</sup>. Nine of the previous 11  
5 RTNano<sup>-</sup>/PCR<sup>+</sup> samples were identified as SARS-CoV-2<sup>+</sup>, suggesting an improved sensitivity  
6 (Supplementary File 3). The average N1 CT value of POS\_1 was improved from 30.48 to 32.06  
7 (Supplementary Fig. 2f). Using the new data, we calculated the LoD of SARS-CoV-2 of 7-amplicon  
8 NIRVANA was ~20 viral RNA copies/μl of extracted nucleic acid (61 copies per reaction, based on  
9 average N1 CT value of 33.37 of POS\_0).

10

11 The sensitivity of FluA detection was also improved as two FluA<sup>+</sup> samples (Resp'Easy<sup>TM</sup> CT value of 33.97  
12 and 36.03) were correctly identified (sample 46 & 58 in Supplementary Fig. 2e, Supplementary Fig. 2g).  
13 The HCoV<sup>+</sup> sample was still not identified. Since NIRVANA showed a robust ability in detecting HCoV in  
14 the positive control sample (Fig. 2a), we suspected that the HCoV in the clinical sample may belong to a  
15 different strain that could not be amplified by our HCoV primers. Taken all together, these results  
16 showed that NIRVANA provided high-confident SARS-CoV-2 detection for virus loads above 20 copies/μl  
17 of extracted nucleic acid and reliable capability in detecting potential co-infections.

18

19 RTNano has an integrated function to quickly analyze variants in each sample during sequencing. We  
20 used it to analyze sequence variants in ten SARS-CoV-2 positive samples (Fig. 1d). It detected 16 single  
21 nucleotide variants (SNVs) in the ten samples and all of them had been reported in GISAID (Fig. 2f, as of  
22 June 7, 2020). The reported SNVs suggested that the strains in samples 01-03 are close to clade 19B  
23 (nt28144 T/C), first identified in Wuhan, China, while the strains in samples 04-10 are close to clade 20  
24 (nt14408 C/T, 23403 A/G), first becoming endemic in Europe. Given the fact that samples 01-03 were  
25 collected early in the pandemic, while the others were later (around May), the SNV signature of the  
26 strains revealed by NIRVANA is consistent with the pattern of COVID-19 case importation, which initially  
27 came from China and shifted to Europe after a ban of flight from China. Prospectively collecting such  
28 data regularly could guide public health policy making to better control the pandemic.

29

30 To validate the SNVs and compare NIRVANA with conventional RT-PCR amplicon sequencing<sup>28</sup>, we chose  
31 three samples (01-03) to perform multiplex RT-PCR amplicon sequencing on the Nanopore MinION.  
32 Variant calling was done by RTNano using the same parameters and the results showed that RT-PCR



1 sequencing confirmed all 3 SNVs detected by NIRVANA ([Supplementary Fig. 3a](#)). We further compared  
2 the SNVs of samples 01-03 with their corresponding assembled genome from Illumina sequencing  
3 published in GISAID (EPI\_ISL\_437459 for sample03, EPI\_ISL\_437460 for sample04, and EPI\_ISL\_437461  
4 for sample05). All of the three SNVs existed in the assembled genome.

5  
6 Taken together, NIRVANA provides high-confidence detection of both SARS-CoV-2 and other respiratory  
7 viruses, and mutation surveillance of SARS-CoV-2 on the fly. Compared to the Oxford Nanopore's official  
8 method termed LAMPore<sup>29</sup>, which is based on RT-LAMP, NIRVANA offers several advantages including  
9 longer amplicons and higher level of multiplexing. LAMPore generated short amplicons (~80 bp), of  
10 which half was composed of primer sequences. Thus, the read alignment may be more prone to  
11 amplification artifacts that lead to false-positive calling. In NIRVANA, significantly longer amplicons (up  
12 to 466 bp in this study) combined with alignment record filter can significantly improve the accuracy of  
13 positive result by eliminating the influence of amplification artifacts. In addition, LAMP-based LAMPore  
14 requires multiple primers (at least 4) to amplify one amplicon, which was challenging for multiplexing. In  
15 contrast, we showed that RPA-based NIRVANA is able to amplify and detect nine amplicons in one pot  
16 ([Fig. 2a](#)). It holds great promise in detecting multiple viruses simultaneously to help monitor and control  
17 the pandemic and the treatment of patients.

18  
19 The whole workflow of NIRVANA can be further shortened by performing one-pot RT-RPA  
20 ([Supplementary Fig. 1d](#)) so that the time from RNA to answer can be as short as 3.5 hours. All molecular  
21 biology reactions in the workflow can be done in a simple heating block, and all necessary supplies fit  
22 into a briefcase ([Supplementary Fig. 3b](#)). The framework of NIRVANA was built with flexibility of  
23 detecting other viruses by changing primers. We expect it to provide a rapid field-deployable solution of  
24 pathogen detection and surveillance of pandemic strains.

25  
26

## 1    **METHODS**

2

### 3    *RNA samples and primers*

4

5    Anonymized RNA samples were obtained from Ministry of Health (MOH) hospitals in the western region  
6    in Saudi Arabia. The use of clinical samples in this study is approved by the institutional review board  
7    (IRB# H-02-K-076-0320-279) of MOH and KAUST Institutional Biosafety and Bioethics Committee (IBEC).  
8    Oropharyngeal and nasopharyngeal swabs were carried out by physicians and samples were steeped in  
9    1 mL of TRIzol (Invitrogen Cat. No 15596018) to inactivate virus during transportation. Total RNA  
10    extraction of the samples was performed following instructions as described in the CDC EUA-approved  
11    protocol using the Direct-Zol RNA Miniprep kit (Zymo Research Cat. No R2070) or TRIzol reagent  
12    (Invitrogen Cat. No 15596026) following the manufacturers' instructions. The Respiratory (21 targets)  
13    control panel (Microbiologics Cat. No 8217) was used as positive control in the amplification of FluA,  
14    HAdVs and HCoV. A list of primers used in this study can be found in [Supplementary table 1](#).

15

### 16    *Wastewater samples*

17

18    Raw sewage was collected at 9 AM and 4 PM on 7 June 2020 from the wastewater equalization tank in  
19    KAUST, and then mixed together to constitute a composite sample. A 300-500 ml of sewage mixture was  
20    concentrated by electronegative membrane in the present of cation as previously described<sup>30</sup>. The  
21    eluate of viruses was recovered in a tube with 50  $\mu$ L of 100 mM H<sub>2</sub>SO<sub>4</sub> (pH 1.0) and 100  $\mu$ L of 100 $\times$  Tris–  
22    EDTA buffer (pH 8.0) for neutralization. Centriprep YM-50 (Merck Millipore) was used to further  
23    concentrate the samples to a volume of 600-700  $\mu$ L.

24

### 25    *Reverse transcription*

26

27    Reverse transcription of RNA samples was done using either NEB ProtoScript II reverse transcriptase  
28    (NEB Cat. No M0368) or Invitrogen SuperScript IV reverse transcriptase (Thermo Fisher Scientific Cat. No  
29    18090010), following protocols provided by the manufacturers. After reverse transcription, 5 units of  
30    thermostable RNase H (New England Biolabs Cat. No M0523S) was added to the reaction, which was  
31    incubated at 37 °C for 20 min to remove RNA. The final reaction was diluted to be used as templates in  
32    RPA. All of the web-lab experiments in this study were conducted in a horizontal flow clean bench to

1 prevent contaminations. The bench was decontaminated with 70% ethanol, DNAZap (Invitrogen, Cat no.  
2 AM9890) and RNase AWAY (Invitrogen, Cat no. 10328011) before and after use. The filtered pipette tips  
3 (Eppendorf epT.I.P.S.® LoRetention series) and centrifuge tubes (Eppendorf DNA LoBind Tubes, Cat. No  
4 0030108051) used in this study were PCR-clean grade. All of the operations were performed carefully  
5 following standard laboratory operating procedures.

6

#### 7 *rRT-PCR*

8

9 The rRT-PCR assay of SARS-CoV-2 was purchased from IDT (Cat. No 10006770). The rRT-PCR assay for  
10 FluA was purchase from IDT (Cat. No 1079729). Respiratory Virus PCR Panel kit (Diagenode diagnostics,  
11 DDGR-90-L048) was used for the determination of FluA, HAdVs and HCoV. All reactions were run on a  
12 CFX384 Touch Real-Time PCR Detection System (Bio-rad) following the instruction of manufacturers. The  
13 copy number of SARS-CoV-2 is determined by the IDT SARS-CoV-2 rRT-PCR assay based on the standard  
14 curve of CT values of known copies of synthetic SARS-CoV-2 N gene RNA (nt28,287-29,230 in  
15 NC\_045512.2, DNA template purchased from IDT). A serial dilution of the synthetic RNA is performed to  
16 obtain final concentrations of 10, 10<sup>2</sup>, 10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, 10<sup>6</sup>, 10<sup>7</sup> copies/μl. The reverse transcription is done  
17 using 1 μl of diluted RNA, followed by rRT-PCR using 2.5 μl of 5-fold diluted cDNA.

18

#### 19 *Singleplex RPA*

20

21 Singleplex RPA was performed using TwistAmp® Basic kit following the standard protocol. Thirteen pairs  
22 of SARS-CoV-2 primers covering N gene, S gene, ORF1ab and ORF8 were tested and the corresponding  
23 amplicons were purified by 0.8X Beckman Coulter AMPure XP beads (Cat. No A63882) and eluted in 40  
24 μl H<sub>2</sub>O. The purified amplicons were first analyzed by running DNA agarose gel to check the specificity  
25 and efficiency. The most robust five pairs of primers with correct size were further analyzed by NlaIII  
26 (NEB Cat. No R0125L) and SpeI (NEB Cat. No R0133L) digestion following standard protocols. For one-pot  
27 RT-RPA, 10 U of AMV Reverse Transcriptase (NEB Cat no. M0277S) and 20 U of SUPERase•In™ RNase  
28 Inhibitor (Invitrogen Cat no. AM2694) were added to a regular RPA reaction mix. The RT-RPA was carried  
29 out per the manufacturer protocol. For the RPA of respiratory viruses, reverse-transcribed cDNA from  
30 the Respiratory (21 targets) control panel (Microbiologics Cat. No 8217) was used as the template.

31

#### 32 *Multiplex RPA*

1  
2 Multiplex RPA was done by add all of the primers in the same reaction. The total final primer  
3 concentration is set to 2  $\mu\text{M}$ . To achieve an even and robust amplification, we empirically determined  
4 the final concentration of the five-amplicon primers (for the initial test of 10 SARS-CoV-2 positive  
5 samples) as follows: 0.166  $\mu\text{M}$  for each pair-4 primer, 0.166  $\mu\text{M}$  for each pair-5 primer, 0.242  $\mu\text{M}$  for  
6 each pair-9 primer, 0.26  $\mu\text{M}$  for each pair-10 primer, 0.166  $\mu\text{M}$  for each pair-13 primer, 29.5  $\mu\text{l}$  of primer  
7 free rehydration buffer, 1  $\mu\text{l}$  of 10-fold diluted cDNA, 7 $\mu\text{l}$  H<sub>2</sub>O. In the multiplex RPA of 9-amplicon and 7-  
8 amplicon (remove pair 9 & 10) primers, the primer mixtures were obtained by combining different  
9 amount of 10  $\mu\text{M}$  primers according to the ratios in [Supplementary table 1](#), and 2.5  $\mu\text{l}$  of 5-fold diluted  
10 cDNA were used as template. The reaction was incubated at 39 °C for 4 min, then vortexed and spin  
11 down briefly, followed by a 16-min incubation at 39 °C.

### 12 13 *Library preparation and sequencing*

14  
15 The RPA library preparation was done using Native barcoding expansion kit (Oxford Nanopore  
16 Technologies EXP-NBD114 and EXP-NBD196) following Nanopore PCR tiling of COVID-19 Virus protocol  
17 (Ver: PTC\_9096\_v109\_revE\_06Feb2020) with a few changes to save time. The RPA reaction was purified  
18 using Qiagen QIAquick PCR purification kit (Qiagen Cat No. 28106) and elute in 30  $\mu\text{l}$  H<sub>2</sub>O. The end-prep  
19 reaction was done separately in 15  $\mu\text{l}$  volume using 5  $\mu\text{l}$  of each multiplex RPA samples. After that, we  
20 followed the same procedures as described in the official protocol. The RT-PCR library preparation was  
21 done using Native barcoding expansion kit (Oxford Nanopore Technologies EXP-NBD104) according to  
22 the standard native barcoding amplicons protocol. The sequencing runs were performed on an Oxford  
23 Nanopore MinION sequencer using R9.4.1 flow cells.

### 24 25 *Bioinformatics*

26  
27 RTNano scanned the sequencing folder repeatedly based on user defined interval time. Once newly  
28 generated fastq files were detected, it moved the files to the analysis folder and made a new folder for  
29 each sample. If the Nanopore demultiplexing tool guppy is provided, RTNano will do additional  
30 demultiplexing to make sure reads are correctly classified. The analysis part utilized minimap2<sup>31</sup> to  
31 quickly align the reads to the SARS-CoV-2 reference genome (GenBank: NC\_045512). After alignment,  
32 RTNano will filter the alignment records based on defined thresholds of parentage identity and amplicon

1 coverage, followed by counting the alignment records of each amplicon. A read with  $\geq 89\%$  alignment  
2 identity and  $\geq 96\%$  amplicon coverage will be counted as one positive record. If an NTC barcode  
3 number was provided, RTNano will subtract this number in individual sample analysis to further ensure  
4 confident demultiplexing. In the end, RTNano will assign samples with different result marks (POS, NEG  
5 and UNK) based on the number of alignment records of each amplicon. With the sequencing continuing,  
6 RTNano will merge the newly analyzed result with completed ones to update the current sequencing  
7 statistics. RTNano is ultra-fast, a typical analysis with additional guppy demultiplexing of 5 fastq files  
8 (containing 4000 reads each and sequenced with 12-barcode kit) will take  $\sim 10$ s using one thread in a  
9 MacBook Pro 2016 15-inch laptop. Variant calling was performed using samtools (v1.9) and bcftools  
10 (v1.9)<sup>32</sup>. The detected variants were filtered by position (within the targeted regions) and compared with  
11 the data in Nextstrain.org as of Jun 2, 2020.

12

### 13 *Data and materials availability*

14

15 RTNano and sample data in this study are accessible at GitHub (<https://github.com/milesjor/RTNano>).

1 REFERENCE:

- 2
- 3 1 WHO. *Naming the coronavirus disease (COVID-19) and the virus that causes it*,  
4 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
5 [guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
6 (2020).
- 7 2 The nCoV Outbreak Joint Field Epidemiology Investigation Team, Q., Li. An Outbreak of  
8 NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province, 2019–2020. *China CDC*  
9 *Weekly* **2**, 79-80, doi:10.46234/ccdcw2020.022 (2020).
- 10 3 Wu, F., Zhao,S., Yu,B., Chen,Y.M., Wang,W., Song,Z.G., Hu,Y., Tao,Z.W., Tian,J.H., Pei,Y.Y.,  
11 Yuan,M.L., Zhang,Y.L., Dai,F.H., Liu,Y., Wang,Q.M., Zheng,J.J., Xu,L., Holmes,E.C. and  
12 Zhang,Y.Z. Novel 2019 coronavirus genome. (2020).
- 13 4 Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-  
14 PCR. *Euro Surveill* **25**, doi:10.2807/1560-7917.ES.2020.25.3.2000045 (2020).
- 15 5 Centers for Disease Control and Prevention, R. V. B., Division of Viral Diseases. Real-Time  
16 RT-PCR Panel for Detection 2019-Novel Coronavirus. (2020).
- 17 6 Zhang, Y. Z. & Holmes, E. C. A Genomic Perspective on the Origin and Emergence of  
18 SARS-CoV-2. *Cell* **181**, 223-227, doi:10.1016/j.cell.2020.03.035 (2020).
- 19 7 Lansbury, L., Lim, B., Baskaran, V. & Lim, W. S. Co-infections in people with COVID-19: a  
20 systematic review and meta-analysis. *J Infection* **81**, 266-275,  
21 doi:10.1016/j.jinf.2020.05.046 (2020).
- 22 8 Babiker, A. *et al.* Metagenomic sequencing to detect respiratory viruses in persons  
23 under investigation for COVID-19. *J Clin Microbiol*, doi:10.1128/JCM.02142-20 (2020).
- 24 9 Hashemi, S. A., Safamanesh, S., Zadeh-moghaddam, H. G., Ghafouri, M. & Azimian, A.  
25 High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients  
26 in Northeastern Iran. *Journal of Medical Virology*, doi:10.1002/jmv.26364 (2020).
- 27 10 Notomi, T. *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic acids research*  
28 **28**, E63, doi:10.1093/nar/28.12.e63 (2000).
- 29 11 Zhang, Y. *et al.* Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using  
30 Colorimetric LAMP. *medRxiv*, 2020.2002.2026.20028373,  
31 doi:10.1101/2020.02.26.20028373 (2020).
- 32 12 Yan, C. *et al.* Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a  
33 reverse transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect*  
34 **26**, 773-779, doi:10.1016/j.cmi.2020.04.001 (2020).
- 35 13 Broughton, J. P. *et al.* CRISPR-Cas12-based detection of SARS-CoV-2. *Nature*  
36 *biotechnology*, doi:10.1038/s41587-020-0513-4 (2020).
- 37 14 Joung, J. *et al.* Point-of-care testing for COVID-19 using SHERLOCK diagnostics. *medRxiv*,  
38 2020.2005.2004.20091231, doi:10.1101/2020.05.04.20091231 (2020).
- 39 15 Gardy, J. L. & Loman, N. J. Towards a genomics-informed, real-time, global pathogen  
40 surveillance system. *Nature reviews* **19**, 9-20, doi:10.1038/nrg.2017.88 (2018).
- 41 16 Greninger, A. L. *et al.* Rapid metagenomic identification of viral pathogens in clinical  
42 samples by real-time nanopore sequencing analysis. *Genome Med* **7**, 99,  
43 doi:10.1186/s13073-015-0220-9 (2015).

- 1 17 Bi, C. *et al.* Long-read Individual-molecule Sequencing Reveals CRISPR-induced Genetic  
2 Heterogeneity in Human ESCs. *bioRxiv*, 2020.2002.2010.942151,  
3 doi:10.1101/2020.02.10.942151 (2020).
- 4 18 Li, Y. *et al.* DeepSimulator1.5: a more powerful, quicker and lighter simulator for  
5 Nanopore sequencing. *Bioinformatics* **36**, 2578-2580,  
6 doi:10.1093/bioinformatics/btz963 (2020).
- 7 19 Yin, C. Genotyping coronavirus SARS-CoV-2: methods and implications. *Genomics*,  
8 doi:10.1016/j.ygeno.2020.04.016 (2020).
- 9 20 Pachetti, M. *et al.* Emerging SARS-CoV-2 mutation hot spots include a novel RNA-  
10 dependent-RNA polymerase variant. *J Transl Med* **18**, 179, doi:10.1186/s12967-020-  
11 02344-6 (2020).
- 12 21 Kim, D., Quinn, J., Pinsky, B., Shah, N. H. & Brown, I. Rates of Co-infection Between  
13 SARS-CoV-2 and Other Respiratory Pathogens. *Jama-J Am Med Assoc* **323**, 2085-2086,  
14 doi:10.1001/jama.2020.6266 (2020).
- 15 22 Ma, L. *et al.* Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. *Infect Drug*  
16 *Resist* **13**, 3045-3053, doi:10.2147/IDR.S267238 (2020).
- 17 23 Medema, G., Heijnen, L., Elsinga, G., Italiaander, R. & Brouwer, A. Presence of SARS-  
18 Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in  
19 the Early Stage of the Epidemic in The Netherlands. *Environmental Science & Technology*  
20 *Letters* **7**, 511-516, doi:10.1021/acs.estlett.0c00357 (2020).
- 21 24 Kitajima, M., Sassi, H. P. & Torrey, J. R. Pepper mild mottle virus as a water quality  
22 indicator. *Npj Clean Water* **1**, doi:ARTN 19 10.1038/s41545-018-0019-5 (2018).
- 23 25 Surkova, E., Nikolayevskyy, V. & Drobniowski, F. False-positive COVID-19 results: hidden  
24 problems and costs. *Lancet Respir Med*, doi:10.1016/S2213-2600(20)30453-7 (2020).
- 25 26 Katz, A. P. *et al.* False-positive reverse transcriptase polymerase chain reaction screening  
26 for SARS-CoV-2 in the setting of urgent head and neck surgery and otolaryngologic  
27 emergencies during the pandemic: Clinical implications. *Head Neck-J Sci Spec* **42**, 1621-  
28 1628, doi:10.1002/hed.26317 (2020).
- 29 27 Vogels, C. B. F. *et al.* Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-  
30 qPCR primer-probe sets. *Nat Microbiol* **5**, 1299+, doi:10.1038/s41564-020-0761-6  
31 (2020).
- 32 28 Team, C.-I. Clinical and virologic characteristics of the first 12 patients with coronavirus  
33 disease 2019 (COVID-19) in the United States. *Nature medicine*, doi:10.1038/s41591-  
34 020-0877-5 (2020).
- 35 29 James, P. *et al.* LamPore: rapid, accurate and highly scalable molecular screening for  
36 SARS-CoV-2 infection, based on nanopore sequencing. *medRxiv*,  
37 2020.2008.2007.20161737, doi:10.1101/2020.08.07.20161737 (2020).
- 38 30 Haramoto, E., Katayama, H. & Ohgaki, S. Detection of noroviruses in tap water in Japan  
39 by means of a new method for concentrating enteric viruses in large volumes of  
40 freshwater. *Appl Environ Microb* **70**, 2154-2160, doi:10.1128/Aem.70.4.2154-2160.2004  
41 (2004).
- 42 31 Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094-  
43 3100, doi:10.1093/bioinformatics/bty191 (2018).

1 32 Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,  
2 2078-2079, doi:10.1093/bioinformatics/btp352 (2009).  
3  
4  
5

## 6 **Acknowledgements**

7 We thank members of the Li laboratory, Baolei Yuan, Xuan Zhou, Yingzi Zhang, and Samhan Alsolami for  
8 helpful discussions; Marie Krenz Y. Sicat for administrative support. We thank members of the Pain lab,  
9 Rahul Salunke and Amit Subudhi for technical assistance. We thank members of the Izpisua Belmonte  
10 lab, Yanjiao Shao, Yasuo Ouchi, and Pradeep Reddy for generously sharing ideas of simultaneous  
11 pathogen detection. We thank Professor Peiyong Hong and her lab members, Dr. Andri Rachmadi and Dr.  
12 David Mantilla-Calderon for kindly sharing wastewater samples and technical assistance.  
13

## 14 **Author contributions**





15 ML and CB performed majority of the experiments related to Nanopore sequencing. GM and CB  
16 performed diagnosis assays for various viral pathogens. CB wrote the code and performed the  
17 bioinformatics analysis. ML, CB, JX and CRE designed and performed molecular biology experiments. FSA,  
18 AK, AMH, and NAMA collected clinical samples. SM extracted RNA and performed molecular assays. SH  
19 and AP coordinated the clinical samples and molecular testing. CB, GM, YT, END, JCBI and ML analyzed  
20 the data and wrote the manuscript. ML, CB and JCBI conceived the study. JCBI and ML supervised the  
21 study.  
22

## 23 **Funding**

24 The research of the Li laboratory was supported by KAUST Office of Sponsored Research (OSR), under  
25 award numbers BAS/1/1080-01. The work was supported by a KAUST Competitive Research Grant  
26 (award number URF/1/3412-01-01) given to ML and JCIB. This work was supported by Universidad  
27 Catolica San Antonio de Murcia (JCIB). AMH is supported by funding from the deputyship for Research  
28 and Innovation, Ministry of Education in Saudi Arabia (project number 436).  
29  
30



## 1 Main Figures



2

3

1 **Figure 1. Multiplex RPA workflow for SARS-CoV-2 detection and Nanopore sequencing**

2 a, Schematic representation of NIRVANA. RNA samples were subjected to reverse transcription,  
3 followed by multiplex RPA to amplify multiple regions of the SARS-CoV-2 genome. The amplicons were  
4 purified and prepared to the Nanopore library using an optimized barcoding library preparation protocol.  
5 In the end, the sequencing was performed in the pocket-sized Nanopore MinION sequencer and  
6 sequencing results were analyzed by our algorithm termed RTNano on the fly.

7 b, The RPA primers used in this study were plotted in the SARS-CoV-2 genome. The RPA amplicons are  
8 highlighted in red. The corresponding prevalent variants were labeled under the genome.

9 c, Agarose gel electrophoresis results of multiplex RPA. All of the five amplicons were shown in the gel  
10 with correct size (asterisks, note that pair 5 and 13 have similar sizes). The no template control (NTC)  
11 showed a different pattern of non-specific amplicons. M: molecular size marker.

12 d, IGV plots showing Nanopore sequencing read coverage of the SARS-CoV-2 genome. All samples  
13 showed reads covering all of the targeted regions.


14 e, Pipeline of RTNano real-time analysis. RTNano monitors the Nanopore MinION sequencing output  
15 folder. Once newly generated fastq files are detected, it moves the files to the analyzing folder and  
16 makes a new folder for each sample. If the Nanopore demultiplexing tool guppy is provided, RTNano will  
17 do additional demultiplexing to make sure reads are correctly classified. The analysis will align reads to  
18 the SARS-CoV-2 reference genome, filter, and count alignment records, and assign result mark (POS,  
19 NEG or UNK) for each sample. As sequencing proceeds, RTNano will merge the newly analyzed results  
20 with existing ones to update the current sequencing statistics.

21

22

23

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1 **Figure 2. Real-time detection of multiple viral pathogens and mutational analysis of SARS-CoV-2**

2 **a**, Experimental design of multiple virus detection by one-pot NIRVANA. A mixture of SARS-CoV-2<sup>+</sup> and  
3 Respiratory21<sup>+</sup> samples was used as positive control to adjust the primer concentration. The final primer  
4 mix could amplify all targeted viral regions.

5 **b**, The sequencing throughput of 60 clinical samples (1-60) and NTC (61). A total of 6.3 million reads  
6 were acquired in a 24-hour sequencing run.

7 **c**, CT values of potentially false-negative samples by RTNano analysis. The average CT value of the N1  
8 assay was indicated by the blue line.

9 **d**, The average rRT-PCR CT values of SARS-CoV-2 RTNano<sup>+</sup> samples (PCR<sup>+</sup> of both N1 and N2 assays) of  
10 different confidence level using 9-amplicon NIRVANA. The sample number is shown in red under the  
11 graph. RTNano confidence level inversely correlates with CT value.

12 **e**, IGV plots showing the read alignment to the SARS-CoV-2, *ACTB*, and FluA amplicon in sample 46 using  
13 9-amplicon NIRVANA.

14 **f**, The SNVs detected in multiplex RPA sequencing and their position as shown in the Nextstrain data  
15 portal (Nextstrain.org). A total of 16 SNVs were detected from 10 SARS-CoV-2 positive samples.


16

17


18

## 1 Supplementary Figures


a




b



c



d



2

1 **Supplementary Figure 1. Agarose gel electrophoresis results of singleplex RPA**

2 **a**, Agarose gel electrophoresis results of singleplex RPA with selected primers shown next a molecular  
3 size marker. The amplicons range from 194 bp to 466 bp.

4 **b**, Agarose gel electrophoresis results of restriction enzyme digestion. The amplicon of pair 5 was  
5 digested by SpeI while the others were digested by NlaIII. The digested DNA bands (asterisks) were of  
6 expected sizes.


7 **c**, Agarose gel electrophoresis results showing the sensitivity of RPA in amplifying the SARS-CoV-2  
8 genome. Primer pair 4 was used in the experiment. Reliable amplification can be achieved with 1.4 copies  
9 (calculated from dilution) of the SARS-CoV-2 genome.

10 **d**, Agarose gel electrophoresis result of one-pot reverse transcription and RPA reaction using primer pair  
11 4.

12

13

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1 **Supplementary Figure 2. Sequencing analysis of multiplex RPA**

2 **a**, The read length distribution and throughput of ten SAR-CoV-2<sup>+</sup> sample sequencing.

3 **b**, The read number for each amplicon in the sequencing of ten SAR-CoV-2<sup>+</sup> samples. All amplicons  
4 were covered by reads.

5 **c**, The read number for each amplicon in the trial sequencing of multiplex RPA of SARS-CoV-2 and  
6 *ACTB*. Sample 01 is used as RPA template to determine the primer concentration in two trials  
7 (sample01\_1 and sample01\_2). Sample 02 is used in a repeat trial using the same primer mix as  
8 sample01\_2.

9 **d**, The IGV alignment plot showing robust amplification of PMMoV with SARS-CoV-2. A SARS-CoV-  
10 2<sup>+</sup> sample (S4) was used as input sample in two trials with different primer concentration.

11 **e**, The CT values of FluA<sup>+</sup> samples in Resp'Easy<sup>TM</sup> and IDT FluA assays.


12 **f**, The average rRT-PCR CT values of SARS-CoV-2 RTNano<sup>+</sup> samples (PCR<sup>+</sup> of both N1 and N2 primers)  
13 of different confidence level using 7-amplicon NIRVANA.

14 **g**, IGV plots showing the read alignment to SARS-CoV-2, *ACTB* and FluA amplicon in sample 58 using  
15 7-amplicon NIRVANA.

16

17





**b**



1

1 **Supplementary Figure 3. Validation of SNVs detected by NIRVANA**

2 **a**, IGV plots showing the nt28144 T/C SNV in samples 01-03 from RPA and RT-PCR Nanopore  
3 sequencing. The blue bar represents the C base while the red bar represents the T base. All of the 3 SNVs  
4 detected in RPA sequencing were confirmed by RT-PCR amplicon sequencing.

5 **b**, Equipment used in NIRVANA. The whole workflow can be done with one laptop, one Nanopore  
6 MinION sequencer, two pipettes, two boxes of pipette tips, and a heating block (using a miniPCR™  
7 mini16 here). All equipment can be packed into a suitcase.

8

9

10